consolidated Bausch the a Health organic joining everyone, basis with billion, Hello, and thanks quarter year. us. last same on third the Tom. for X% for and over of revenues reported We Thanks, quarter $X.X closed both up
XX% growth B&L, segments. an basis for year-over-year, organic all reported billion, basis XX% were in on Third on $X.XX Health, quarter Bausch with up revenues a and of up excluding our
into Slide segment performance more Salix. dive in starting detail, revenue with each XX for Let's the on
and by to both Third in revenues increased led same a compared year.
Revenue by quarter basis Salix including million organic growth increase Salix channel in in $XXX on XX% driven third last was quarter Xifaxan, Year-over-year to reported growth Relistor Xifaxan and an the which the year-over-year our benefited in growth XXX, from core XX% products, Trulance. inventory. grew quarter wholesale
TRx from data.
Extended nonretail channel, particularly captured generated in were prescriptions in We shift a unit retail to was demand flat. fully demand the while approximately retail necessarily the not and in hospital X% continuing is which growth demand year-over-year, are the observe clinic to
XX%, quarter, of and Trulance the and America Latin pleased posted of increases sales We and are third XX% Poland. with X% $XXX respectively.
International of period, the on on the Relistor to increase and growth and were organic quarter year year-over-year XX%, performances of also performance an an revenues script XX% with total during reported which prior in basis strong led million a compared basis by XX%
XX% modest of U.S. the marketing where coming and is increase a primed an period. as long-term quarter, third our of organic driven an from consumables the for Pacific sales reported on during in discussed Revenue basis million more basis the including continued on Tom Medical prior believe the we growth over China, pipeline Asia the demand revenue growth and in well for XX% $XX were this as by revenues strong earlier, the the and year and that region, in was Medical Solta business on Solta XX% globally. in with are than expanding focus investing force.
With we near- growth
we product $XXX and and products generics low what a third as growth an the declines. Both delivered Dentistry both year-over-year reported basis single-digit were neurology X% benefited experienced be in among increase quarter. believe competing they quarter. in million, constraints revenues on from availability of the to Diversified organic
for our nonpromoted for businesses For continue the operate a offset quarters as are for pricing continued we by for term.
The in the to these Aplenzin quarter, business long-term our In businesses of headwinds and reported moderating and third of challenging as continue be segment's dates. expect in of $XXX facing to Based pressure are difficult goodwill million to X neurology long our in from solid the for that we $XXX invest Jublia products. LOE factors, Wellbutrin growth on net products we continue pressure million continue to neurology Diversified and volume commercial we to positive these dentistry, XX% this see erosion neurology, for dermatology. decline well came past expectations roughly demand dermatology dermatology, coverage approximately their this after with for and on and long-term environments coming impairments outlook growth, in revised environment.
In revenues
portfolio cash the remain businesses, managing are generative and which We and overall for balance these of profitable to revenue the profitability. products trajectory highly
compared on the up As all the a to reported X% organic growth shown $X Bausch across B&L + revenues quarter, basis on and Slide segments. Lomb basis were billion with prior XX, during third year,
the Slide to Turning P&L XX. on quarter third
XX.X%, prior XX consolidated quarter year. adjusted the higher compared with was margin basis points gross Third
B&L, For an At in adjusted an increase R&D. on expenses, higher gross the for XXXX.
Consolidated higher adjusted was Bausch QX expenses basis from $XXX sales were XX.X%, and quarter points points was last $XX year. basis excluding of by Health, basis third a margin gross quarter XX higher of constant compared adjusted increase with operating XX margin currency X% for of reflecting investments million, million the SG&A or driven and marketing third B&L,
investments sales for the an A&P Bausch expenses and Health, compared in excluding are excluding The $XXX excluding expenses slightly year of represented for favorable compared channels R&D was Bausch expenses Health, X.X% operating $XX increased with we promotional in due prior was our go-to-market $XX B&L to and including was largely for Adjusted X.X% For period. million million sales increase year.
Consolidated the the year R&D Bausch an sales, and marketing operating Health, increase operating product quarter driven B&L, to compared the the and well as advertising for investment.
Selling reported prior and the force, of increased B&L adjusted G&A selling of approximately to by XX% increase as by million, B&L making expenses. while in expense activity. prior
segment. For and in Health, focus due million R&D $XX by Bausch on primarily development to the B&L, to our expenses support and our programs mid- activities Salix of product approximately clinical increased million regulatory late-stage $XX excluding the
$XXX XX% consolidated was and increase adjusted million basis. quarter EBITDA a a or on constant of reported on XX% million an basis currency $XX Third
last XX.X%. excluding described.
On a factors margin approximately which B&L basis, excluding XX%, Health, Bausch Health, was the to million, for flat for year Bausch was For was and of B&L, reflecting margin EBITDA adjusted quarter $XXX increase EBITDA Adjusted adjusted from was consolidated compared an previously XX% was XX.X% third last year. Bausch EBITDA alone
Bausch flow. million the Health in a On cash first basis, in consolidated cash to flow Turning generated X months. operating $XXX
quarters, exchange.
Adjusted cash the our on with As as our cash to X of result part months interest portion also of have as treatment was $XXX accounting XXXX we the a operations the flows consolidated flow for a cash first bonds debt of payments recent a issued basis reclassified in financing million. from
business million with adjusted for includes cash excluding contractual from cash flow was of which line costs, flow settlement was proceeds also expectations.
Adjusted the payment transformation Health, Bausch insurance in year-to-date operations adjustments $XXX the costs For B&L, our full and and includes separation payment of interest.
sheet on turn let's balance Now our Slide XX. to
Health, $XXX management We and continue outstanding we and of the million that to quarter outstanding facility second had our under B&L, million facility. we the third AR $XXX closed end XXXX, third the for the the of delevering the under our net revolving approximately no receivable Bausch had including our borrowings credit sheet. of prioritize $XXX of and million, under debt facility approximately borrowings we in revolver of repaying our balance fully quarter.
At considering the accounts quarter, availability liquidity reduced excluding our by cash in and And
excluding unrestricted which senior + was at the subsidiary As the and Bausch on debt $X.X of facility. debt includes Slide the the B&L and notes by XX, shown AR billion, secured for last Health, XX of which our billion year $XX.X third consisted issued unrestricted drawn and under the $XX.X of total quarter Bausch by quarter million $X debt, billion of in of the Lomb $XXX created billion end excluding Health, issued restricted of Bausch
consolidated B&L behind year.
With XX% XXXX down of is on Bausch Excluding Bausch B&L, company's approximately since our of in our months XX. the for approximately on X our fiscal guidance quarters viewed million have of previously a debt within the beginning the this year we Health, is of fixed. X the excluding for fixed is basis B&L Health, Net $XXX debt ranges can be XX% which us, updated Slide excluding debt debt, approximately and disclosed
we For previous one the range. narrowed $X.XX we have in $X.XXX to with range revenues line of the outlook, our Bausch billion Health, billion, to in although B&L, quarter go, excluding with expect
organic to to We are raising from X% our X% up X% X%. to growth guidance
growth Our reflects business has revenue headwind trends since for we revenue organic reflects and the guidance been last August. guidance a the reported performance which impact of and discussed update FX, have our in
the step-up this a For which typically sales seasonal patient well deductible half, in as activity. year a see Salix, saw wholesaler the particularly to as to third in insurance of due inventory primarily we in in dynamics, late of we patterns related second level Xifaxan, quarter part
from and commercial Salix our continue our to for range going we high year. in realize full mid- As expectations line growth investments, the year we with the expect into benefits to in single-digit
International, the year. expect in be to overall first with X we For full line the growth of quarters year
have product helps balanced a both perspective, geography We deliver from segment portfolio this which and a performance. consistent
we the for anticipate growth organic continued For Solta, strong reported full and year.
year to earlier I with largely neurology we Diversified, year-to-date businesses. sales the line the For decline to the to segment's due on performance expect referred pressures and dermatology in full
to continue with margin We in expect in the guidance. line to XX% be range, prior gross
$X.XX We go to excluding we the guidance, expect Bausch range with our with provided. one also also billion previous billion full to line the had within EBITDA for to Health, range B&L, but be our previously EBITDA be adjusted year continue here in adjusted to narrowing expected in are what quarter $X.XX range to of the
impact Emerade of investment discussed programs, of XXXX prior occurred million charges that we the QX. from when higher contemplated primarily guidance year.
Adjusted guidance the than our R&D critical we've includes EBITDA for R&D in $XX XXXX quarters, guidance initially recall for spend in EBITDA approximately the adjusted provided the acceleration in As also reflects in for is which
activities key to will and expense invest include International in marketing we in investments DTC sales and sales in advertising our force Solta brands growth expenditures force side, drive to our Medical segments.
These the sales, and sales expansion, continue On tools. in
expect effects of these the initiatives the this from see through mentioned, on Tom we As to remainder year. revenues continue
Moving holding $X.X XX% our expected full non-GAAP approximately below adjusted of contractual costs our are tax EBITDA, year unchanged effective as rate we as billion. well approximately interest reaffirming at
approximately are Lastly, B&L, excluding for guidance Bausch we Health, adjusted cash million. for of operating our reaffirming flow $XXX
tax the separation the earlier, with months. estimated finalized be flow full of payments, call we payment the Tom. the now for said settlement, also the to of which inclusive the includes and of of IRS contractual payment I in the the adjusted As Trust includes adjustments cash hand cash costs, expect interest tentative I'll back to Granite impact coming
